RIVASTIGMINE GenPar PATCH 15 rivastigmine 13.3 mg/24 hours transdermal drug delivery system sachet

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Compra

Principio attivo:

rivastigmine, Quantity: 27 mg

Commercializzato da:

Arrotex Pharmaceuticals Pty Ltd

INN (Nome Internazionale):

Rivastigmine

Forma farmaceutica:

Drug delivery system, transdermal

Composizione:

Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica

Via di somministrazione:

Transdermal

Confezione:

7 sachets, 30 sachets

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

RIVASTIGMINE GENPAR PATCH is indicated for the treatment of patients with mild, moderate and severe dementia of the Alzheimer?s type.

Dettagli prodotto:

Visual Identification: Circular 15cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 13.3 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2017-01-25